A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Miranda Shea’s gotta have it. “It” being sex, of course. But shortly after beginning a regimen of compounded tirzepatide, the ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

Q1 2025 Earnings Conference Call February 13, 2025 8:00 AM ETCompany ParticipantsSam Fisch - Executive Director, Investor ...

Novo Nordisk shares tumbled last year when obesity candidate CagriSema failed to clear a weight loss bar of 25%. Now, ...

The research adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes. | ITV National News ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

A new study suggests that semaglutide, a drug commonly used for diabetes and obesity, may also help reduce alcohol consumption.

Considering GLP-1 agonists tend to perform better at higher doses, it remains to be seen if Mounjaro 15 mg would outperform ... their weight-loss product as Wegovy. It’s still Ozempic, but ...